Skip Navigation
Skip Website Tools
Showcase Button

Contact Info

NIAID Technology Transfer and Intellectual Property Office
Suite 6D
5601 Fishers Lane, MSC 9804
Telephone: 301-496-2644
Fax: 240-627-3117

Licensing Around the World

NIH Office of Technology Map

Check out a map of NIH Active Licenses around the world. To see only NIAID licenses, select NIAID from the Institute/Center drop-down list and click Submit. You can also filter the map by fiscal year and country.

Technology Transfer and Intellectual Property

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research. But it's a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health. The Technology Transfer and Intellectual Property Office facilitates collaborative relationships between NIAID investigators and the broader scientific community.

View Slides

Highlighted Licensing and Collaboration Opportunities

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

Arsenical Compounds as Therapeutics for Inflammatory Diseases

Anthrax Fusion Toxins With Improved Ability To Penetrate Cells

Multi-Specific Chimeric Antigen Receptors Against HIV

Complete list of Recent Licensing and Collaboration Opportunities

Recent Happenings

United States patent US 8,568,739 was issued on Oct. 29, 2013, for Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses. NIAID inventors: Alexander Pletnev, Ph.D., D.Sci.

NIAID and Gilead Sciences, Inc., signed a CRADA to study the safety and efficacy of Gilead's proprietary compounds including GS7977, GS5885, and GS9669 to treat hepatitis C/HIV co-infection and HCV infection in hard-to-treat populations and identification of the clinical and biological correlates associated with treatment response. NIAID principal investigator: Shyamasundaran Kottilil M.D., Ph.D.

Complete list of Technology Development Recent Happenings

Last Updated June 18, 2014